DK1497417T3 - E-epitoper af EphA2 antigen - Google Patents
E-epitoper af EphA2 antigenInfo
- Publication number
- DK1497417T3 DK1497417T3 DK03740654T DK03740654T DK1497417T3 DK 1497417 T3 DK1497417 T3 DK 1497417T3 DK 03740654 T DK03740654 T DK 03740654T DK 03740654 T DK03740654 T DK 03740654T DK 1497417 T3 DK1497417 T3 DK 1497417T3
- Authority
- DK
- Denmark
- Prior art keywords
- epitopes
- epha2 antigen
- epha2
- antigen
- polynucleotide
- Prior art date
Links
- 102000051096 EphA2 Receptor Human genes 0.000 title abstract 2
- 108010055196 EphA2 Receptor Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0205048A FR2838742B1 (fr) | 2002-04-23 | 2002-04-23 | Epitopes t de l'antigene epha2 |
| PCT/FR2003/001280 WO2003091383A2 (fr) | 2002-04-23 | 2003-04-23 | Epitopes t de l'antigene epha2. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1497417T3 true DK1497417T3 (da) | 2007-06-25 |
Family
ID=28686278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03740654T DK1497417T3 (da) | 2002-04-23 | 2003-04-23 | E-epitoper af EphA2 antigen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060034856A1 (de) |
| EP (1) | EP1497417B1 (de) |
| AT (1) | ATE356867T1 (de) |
| AU (1) | AU2003262810A1 (de) |
| CA (1) | CA2482930C (de) |
| DE (1) | DE60312502T2 (de) |
| DK (1) | DK1497417T3 (de) |
| ES (1) | ES2283791T3 (de) |
| FR (1) | FR2838742B1 (de) |
| PT (1) | PT1497417E (de) |
| WO (1) | WO2003091383A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007527225A (ja) | 2003-07-30 | 2007-09-27 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｅｐｈａ２ｔ−細胞エピトープアゴニストおよびその使用 |
| US7612162B2 (en) | 2004-09-21 | 2009-11-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
| JP5342145B2 (ja) | 2005-02-04 | 2013-11-13 | マクロジェニックス ウエスト， インコーポレイテッド | ＥｐｈＡ２に結合する抗体およびその使用方法 |
| CN101171032B (zh) * | 2005-05-09 | 2012-02-29 | 瓦克松生物技术公司 | 天然肽及其优化的衍生物作为疫苗的应用 |
| AU2008292352B2 (en) | 2007-08-30 | 2012-03-08 | Daiichi Sankyo Company, Limited | Anti-EPHA2 antibody |
| CA3066981A1 (en) | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| US20150079135A1 (en) * | 2012-03-19 | 2015-03-19 | Stemline Therapeutics, Inc. | Methods for treating and monitoring the status of cancer |
| JP2015518835A (ja) | 2012-05-16 | 2015-07-06 | ステムライン セラピューティクス，インコーポレーテッド | 癌幹細胞を標的とした癌ワクチン |
| TWI505113B (zh) * | 2014-03-18 | 2015-10-21 | Vivotek Inc | 監視系統及其影像搜尋方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323016B1 (en) * | 2000-06-09 | 2001-11-27 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| US20040037840A1 (en) * | 2000-10-27 | 2004-02-26 | Beier Anne Mette | Novel therapeutic vaccine formulations |
| AU2003215190A1 (en) * | 2002-02-15 | 2003-09-09 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
-
2002
- 2002-04-23 FR FR0205048A patent/FR2838742B1/fr not_active Expired - Fee Related
-
2003
- 2003-04-23 US US10/511,273 patent/US20060034856A1/en not_active Abandoned
- 2003-04-23 AU AU2003262810A patent/AU2003262810A1/en not_active Abandoned
- 2003-04-23 EP EP03740654A patent/EP1497417B1/de not_active Expired - Lifetime
- 2003-04-23 CA CA2482930A patent/CA2482930C/fr not_active Expired - Fee Related
- 2003-04-23 ES ES03740654T patent/ES2283791T3/es not_active Expired - Lifetime
- 2003-04-23 DE DE60312502T patent/DE60312502T2/de not_active Expired - Lifetime
- 2003-04-23 WO PCT/FR2003/001280 patent/WO2003091383A2/fr active IP Right Grant
- 2003-04-23 PT PT03740654T patent/PT1497417E/pt unknown
- 2003-04-23 DK DK03740654T patent/DK1497417T3/da active
- 2003-04-23 AT AT03740654T patent/ATE356867T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003262810A1 (en) | 2003-11-10 |
| FR2838742A1 (fr) | 2003-10-24 |
| WO2003091383A3 (fr) | 2004-04-01 |
| CA2482930A1 (fr) | 2003-11-06 |
| CA2482930C (fr) | 2013-08-13 |
| AU2003262810A8 (en) | 2003-11-10 |
| PT1497417E (pt) | 2007-06-01 |
| FR2838742B1 (fr) | 2004-07-09 |
| ES2283791T3 (es) | 2007-11-01 |
| US20060034856A1 (en) | 2006-02-16 |
| WO2003091383A2 (fr) | 2003-11-06 |
| EP1497417B1 (de) | 2007-03-14 |
| ATE356867T1 (de) | 2007-04-15 |
| DE60312502D1 (de) | 2007-04-26 |
| EP1497417A2 (de) | 2005-01-19 |
| DE60312502T2 (de) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060998A1 (es) | Anticuerpo monoclonal anti cd40 humana antagonista | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| BRPI0314814C1 (pt) | anticorpo compreendendo uma variante de fc | |
| BR122018016045B8 (pt) | proteína variante otimizada | |
| ATE542829T1 (de) | Impfstoff | |
| CY1118200T1 (el) | Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης | |
| DK2006301T3 (da) | Peptid-baseret immuniseringsterapi til behandling af atherosklerose | |
| AR051942A1 (es) | Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos | |
| CR8231A (es) | Anticuerpos rg1 y uso de los mismos | |
| BRPI0517973B8 (pt) | métodos para purificar o fsh recombinante | |
| CY1114584T1 (el) | Ανασυνδυασμενα εμβολια και χρηση αυτων | |
| CY1112507T1 (el) | Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β | |
| DE602004020189D1 (de) | Adjuvante influenza-vakzine | |
| DK1497417T3 (da) | E-epitoper af EphA2 antigen | |
| DK1409692T3 (da) | Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine | |
| CY1119737T1 (el) | Νεες συνθεσεις και μεθοδοι | |
| NO20062579L (no) | Preparater som omfatter melittin-avledede peptider og fremgangsmate for styrking av immunresponser mot malantigener | |
| CY1107681T1 (el) | Χρηση παραγωγων τροπινεστερα για την παραγωγη φαρμακευτικων μεσων | |
| ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
| WO2004030616A3 (en) | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES | |
| EA200501900A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200501925A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| ES2502366T3 (es) | Inducción de inmunidad tumoral por variantes de proteína de unión a folato | |
| ATE389264T1 (de) | Anfangssynchronisationssuche in einem mobilfunksystem | |
| EA200600455A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей |